ERBB2 and head and neck squamous cell carcinoma: Encouraging preliminary results in R/M SCCHN after failure of a platinum-containing therapy were reported with afatinib, a dual EGFR/Her2 irreversible tyrosine kinase inhibitor, which was compared to single-agent cetuximab in a randomized phase II study.